Triple data take Nuvalent's market cap above $3bn
After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.
Lumakras is the next test of FDA’s hardening stance
After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.
What’s that, a win for CD47?
ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.
Another twist in Cardiff’s onvansertib plan
Front-line phase 3 plans take shape, as the company claims a new success, this time in pancreatic cancer.
Bristol seeks novelty in TIGIT
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
Moderna moves on swiftly with its neoantigen immunotherapy
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
